Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

3CAI

🥰Excellent
Catalog No. T14034Cas No. 28755-03-5

3CAI is a potent and specific AKT1 and AKT2 inhibitor, demonstrating significant inhibition of AKT in an in vitro kinase assay. It suppressed the expression of AKT direct downstream targets (such as mTOR and GSK3β) and induced growth inhibition and apoptosis in colon cancer cells.

3CAI

3CAI

🥰Excellent
Purity: 98.13%
Catalog No. T14034Cas No. 28755-03-5
3CAI is a potent and specific AKT1 and AKT2 inhibitor, demonstrating significant inhibition of AKT in an in vitro kinase assay. It suppressed the expression of AKT direct downstream targets (such as mTOR and GSK3β) and induced growth inhibition and apoptosis in colon cancer cells.
Pack SizePriceAvailabilityQuantity
5 mg$50In Stock
10 mg$70In Stock
25 mg$127In Stock
50 mg$232In Stock
100 mg$348In Stock
200 mg$511In Stock
500 mg$829In Stock
1 mL x 10 mM (in DMSO)$58In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "3CAI"

Select Batch
Purity:98.13%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
3CAI is a potent and specific AKT1 and AKT2 inhibitor, demonstrating significant inhibition of AKT in an in vitro kinase assay. It suppressed the expression of AKT direct downstream targets (such as mTOR and GSK3β) and induced growth inhibition and apoptosis in colon cancer cells.
In vitro
3CAI, a potential AKT inhibitor, exhibits significantly higher potency in inhibiting AKT1 compared to PI3K (60% inhibition at 1 µM vs 10 µM, respectively). In experiments with HCT116 and HT29 colon cancer cells treated with 3CAI (4 µM), I3C, or an AKT inhibitor in 1% FBS/McCoy's 5A (for HCT116) over four days, 3CAI notably increased apoptotic cell numbers versus untreated controls. Additionally, 3CAI markedly reduced AKT-mediated phosphorylation of mTOR (Ser2448) and GSK3β (Ser9) in a time-dependent manner, while also elevating pro-apoptotic proteins p53 and p21 after 12 or 24 hours of treatment. In vitro kinase assays revealed that 3CAI solely inhibits AKT1 kinase activity without affecting the activities of MEK1, JNK1, ERK1, and TOPK at 1 µM. Its capability to suppress AKT1 and AKT2 activities indicates a dose-dependent effect, with a profound impact on downstream AKT targets and the induction of apoptosis.
In vivo
To assess the in vivo antitumor efficacy of 3CAI, athymic nude mice with HCT116 cancer cell-induced tumors on their right flank were orally administered 3CAI at doses of 20 or 30 mg/kg, I3C at 100 mg/kg, or a vehicle control, five times weekly for a duration of 21 days. The higher dosage of 3CAI (30 mg/kg) was found to notably suppress the expression of AKT-target proteins in tumor tissues. Furthermore, this dosage significantly reduced tumor growth by 50% compared to the control group (p<0.05), without inducing noticeable side effects or substantial weight loss in the mice, suggesting a good tolerance to the treatment.
Chemical Properties
Molecular Weight193.63
FormulaC10H8ClNO
Cas No.28755-03-5
SmilesClCC(=O)c1c[nH]c2ccccc12
Relative Density.1.337g/cm3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 246 mg/mL (1270.46 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM5.1645 mL25.8224 mL51.6449 mL258.2244 mL
5 mM1.0329 mL5.1645 mL10.3290 mL51.6449 mL
10 mM0.5164 mL2.5822 mL5.1645 mL25.8224 mL
20 mM0.2582 mL1.2911 mL2.5822 mL12.9112 mL
50 mM0.1033 mL0.5164 mL1.0329 mL5.1645 mL
100 mM0.0516 mL0.2582 mL0.5164 mL2.5822 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy 3CAI | purchase 3CAI | 3CAI cost | order 3CAI | 3CAI chemical structure | 3CAI in vivo | 3CAI in vitro | 3CAI formula | 3CAI molecular weight